Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application

Over the past few decades, we have witnessed a surge around the world in the emergence of antibiotic-resistant bacteria. This global health threat arose mainly due to the overuse and misuse of antibiotics as well as a relative lack of new drug classes in development pipelines. Innovative antibacteri...

Full description

Saved in:
Bibliographic Details
Main Authors: Katarzyna M. Danis-Wlodarczyk (Author), Daniel J. Wozniak (Author), Stephen T. Abedon (Author)
Format: Book
Published: MDPI AG, 2021-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_942a832c7f9f444488e9d78bff5e91d2
042 |a dc 
100 1 0 |a Katarzyna M. Danis-Wlodarczyk  |e author 
700 1 0 |a Daniel J. Wozniak  |e author 
700 1 0 |a Stephen T. Abedon  |e author 
245 0 0 |a Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application 
260 |b MDPI AG,   |c 2021-12-01T00:00:00Z. 
500 |a 10.3390/antibiotics10121497 
500 |a 2079-6382 
520 |a Over the past few decades, we have witnessed a surge around the world in the emergence of antibiotic-resistant bacteria. This global health threat arose mainly due to the overuse and misuse of antibiotics as well as a relative lack of new drug classes in development pipelines. Innovative antibacterial therapeutics and strategies are, therefore, in grave need. For the last twenty years, antimicrobial enzymes encoded by bacteriophages, viruses that can lyse and kill bacteria, have gained tremendous interest. There are two classes of these phage-derived enzymes, referred to also as enzybiotics: peptidoglycan hydrolases (lysins), which degrade the bacterial peptidoglycan layer, and polysaccharide depolymerases, which target extracellular or surface polysaccharides, i.e., bacterial capsules, slime layers, biofilm matrix, or lipopolysaccharides. Their features include distinctive modes of action, high efficiency, pathogen specificity, diversity in structure and activity, low possibility of bacterial resistance development, and no observed cross-resistance with currently used antibiotics. Additionally, and unlike antibiotics, enzybiotics can target metabolically inactive persister cells. These phage-derived enzymes have been tested in various animal models to combat both Gram-positive and Gram-negative bacteria, and in recent years peptidoglycan hydrolases have entered clinical trials. Here, we review the testing and clinical use of these enzymes. 
546 |a EN 
690 |a endolysin 
690 |a EPS depolymerase 
690 |a lysin 
690 |a phage therapy 
690 |a <i>Pseudomonas aeruginosa</i> 
690 |a <i>Staphylococcus aureus</i> 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 10, Iss 12, p 1497 (2021) 
787 0 |n https://www.mdpi.com/2079-6382/10/12/1497 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/942a832c7f9f444488e9d78bff5e91d2  |z Connect to this object online.